- Home
- PAXS vs MESO Comparison
PAXS vs MESO Comparison
Compare PAXS & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PAXS
- MESO
- Stock Information
- Founded
- PAXS 2021
- MESO 2004
- Country
- PAXS United States
- MESO Australia
- Employees
- PAXS N/A
- MESO N/A
- Industry
- PAXS Investment Managers
- MESO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PAXS Finance
- MESO Health Care
- Exchange
- PAXS Nasdaq
- MESO Nasdaq
- Market Cap
- PAXS 757.3M
- MESO 861.6M
- IPO Year
- PAXS N/A
- MESO N/A
- Fundamental
- Price
- PAXS $16.31
- MESO $9.93
- Analyst Decision
- PAXS
- MESO Strong Buy
- Analyst Count
- PAXS 0
- MESO 4
- Target Price
- PAXS N/A
- MESO $11.50
- AVG Volume (30 Days)
- PAXS 195.0K
- MESO 210.7K
- Earning Date
- PAXS 01-01-0001
- MESO 11-28-2024
- Dividend Yield
- PAXS 11.72%
- MESO N/A
- EPS Growth
- PAXS N/A
- MESO N/A
- EPS
- PAXS N/A
- MESO N/A
- Revenue
- PAXS N/A
- MESO $5,902,000.00
- Revenue This Year
- PAXS N/A
- MESO $66.05
- Revenue Next Year
- PAXS N/A
- MESO $348.27
- P/E Ratio
- PAXS N/A
- MESO N/A
- Revenue Growth
- PAXS N/A
- MESO N/A
- 52 Week Low
- PAXS $12.57
- MESO $1.61
- 52 Week High
- PAXS $15.93
- MESO $11.05
- Technical
- Relative Strength Index (RSI)
- PAXS 45.26
- MESO 64.16
- Support Level
- PAXS $16.03
- MESO $9.24
- Resistance Level
- PAXS $16.79
- MESO $10.39
- Average True Range (ATR)
- PAXS 0.28
- MESO 0.61
- MACD
- PAXS -0.10
- MESO 0.02
- Stochastic Oscillator
- PAXS 23.14
- MESO 66.06
About PAXS PIMCO Access Income Fund of Beneficial Interest
PIMCO Access Income Fund is a non-diversified, limited-term, closed-end management investment company. The fund seeks current income as an objective and capital appreciation as a secondary objective. It achieves the investment objectives by utilizing a dynamic asset allocation among multiple sectors in the public and private credit markets, including corporate debt.
About MESO Mesoblast Limited
Mesoblast Ltd is a clinical-stage biotechnology company. It develops and commercializes innovative allogeneic cellular medicines to treat complex diseases resistant to the conventional standard of care. Its portfolio of Phase 3 product candidates comprises remestemcel-L for the treatment of steroid-refractory acute graft versus host disease (SR-aGVHD), and for moderate to severe acute respiratory distress syndrome (ARDS) and others.